Generics & Biosimilars | Association for Accessible Medicines
New Blog - Inflation Rebate Proposal Builds on Bad Policy for Generics
  • Doesn't Add Up patient photo
    Congress Needs To Hear From You!
    Lawmakers are actively considering prescription drug reforms included in the Build Back Better Act (H.R. 5376) that would undermine patient access to affordable FDA-approved generic and biosimilar medicines. Tell your Senator not to put these medicines at risk!
  • AAM 2021 U.S. Generic and Biosimilar Medicines Savings Report. October 2021.
    AAM Encourages Congress to Protect Patient Savings
    Competition from lower-cost generics and biosimilars has successfully led to decades of savings for patients. AAM strongly opposes negotiations in Medicare that would jeopardize these savings.
  • AAM All Access Podcast
    Featured AAM All Access Podcast: Bob Pollock
    Lachman Consultants Senior Advisor Robert (Bob) Pollock shares his experiences at FDA in the early days of the generics industry, the backbone of today's pharmaceutical business.
  • Access! 2022 – AAM Annual Meeting 2022
    Access! 2022
    Access! brings together policymakers, influential speakers and industry leaders to chart the future of generics and biosimilars. Plan to join us in person for the first time since 2019 in Orlando!  Early bird $500 savings off full-pass registration available until December 31, 2021.
  • AAM 2021 U.S. Generic and Biosimilar Medicines Savings Report. October 2021.
    2021 U.S. Generic and Biosimilar Medicines Savings Report
    Report reveals continued savings growth through lower-cost generic and biosimilar competition. The findings reinforce the outsized importance of the industry delivering lifesaving & health-managing medicines.
  • AAM Patient Report: Voices of Access
    Patient Stories: Voices of Access
    AAM's Voices of Access report features patients across the country who tell the impact of accessible generic and biosimilar medicines.

Our Brands and Campaigns

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.